Skin equivalents derived from umbilical cord mesenchymal stem/progenitor cells and umbilical cord epithelial stem/progenitor cells

• US 8,287,854 B2
• Filed: 10/11/2006
• Issued: 10/16/2012
• Est. Priority Date: 10/21/2005
• Status: Active Grant

• Current Assignee: CellResearch Corporation Pte Ltd (CellResearch Group of Cos.)
• Original Assignee: CellResearch Corporation Pte Ltd (CellResearch Group of Cos.)
• Inventors: Phan, Toan-Thang
• Primary Examiner(s): Crouch, Deborah
• Application Number:
  US12/091,018
• Publication Number:
  US 20080248005A1
• Time in Patent Office: 2,197 Days
• Field of Search: None
• US Class Current: 424/93.2
• CPC Class Codes: A61K 35/32 Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
• CPC Class Codes: A61L 27/18 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/3633 Extracellular matrix [ECM]
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/3839 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61L 27/60 Materials for use in artificial skin
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C08L 69/00 Compositions of polycarbonates; Compositions of derivatives of polycarbonates
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2502/094 keratinocytes
• CPC Class Codes: C12N 2502/1323 Adult fibroblasts
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/1369 from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
• CPC Class Codes: C12N 2533/54 Collagen; Gelatin
• CPC Class Codes: C12N 5/0605 : Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0629 : Keratinocytes; Whole skin
• CPC Class Codes: C12N 5/0655 : Chondrocytes; Cartilage
• CPC Class Codes: C12N 5/0668 : Mesenchymal stem cells from other natural sources
• CPC Class Codes: C12N 5/0676 : Pancreatic cells
• CPC Class Codes: C12N 5/0698 : Skin equivalents

Abstract

The present invention relates to a skin equivalent and a method for producing the same, wherein the skin equivalent comprises a scaffold and stem/progenitor cells isolated from the amniotic membrane of umbilical cord. These stem/progenitor cells may be mesenchymal (UCMC) and/or epithelial (UCEC) stem cells, which may then be further differentiated to fibroblast and keratinocytes. Further described is a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The invention also refers to therapeutic uses of these skin equivalents. Another aspect of the invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells. In yet another aspect, the invention relates to a method for generating an insulin-producing cell using stem/progenitor cells isolated from the amniotic membrane of umbilical cord and therapeutic uses thereof. The invention further refers to a method of treating a bone or cartilage disorder using UCMC. Furthermore, the invention refers to a method of generating a dopamin and tyrosin hydroxylase as well as a HLA-G and hepatocytes using UCMC and/or UCEC. The present invention also refers to a method of inducing proliferation of aged keratinocytes using UCMC.

Claims

1. A method of producing a skin equivalent comprising:

providing a scaffold,

providing mammalian cells derived from stem/progenitor cells isolated from the amniotic membrane of umbilical cord and cultivated in serum free media, wherein said cells derived from stem/progenitor cells are selected from the group consisting of mesenchymal stem/progenitor cells (UCMC) and epithelial stem/progenitor cells (UCEC),

placing said UCMC in or onto said scaffold,

incubating said scaffold in a first medium adapted for the cultivation of fibroblast, which allows said UCMC to proliferate and further differentiate into fibroblasts,

placing said UCEC in or onto said scaffold, and

incubating said scaffold in a second medium which allows said UCEC to proliferate and further differentiate into keratinocytes, thereby forming a dermal layer composed of fibroblasts and an epithelial layer composed of keratinocytes.

2. A method according to claim 1, further comprising:

placing an extracellular matrix in or onto said scaffold before placing said UCMC or UCEC in or onto the scaffold.

3. A method according to claim 1, wherein said cells are selected from the group consisting of autologous cells, xenogeneic cells and allogeneic cells.

4. A method according to claim 1, wherein said cells are derived from human cells.

5. A method according to claim 1, wherein said scaffold further comprises at least one cell line, which is able to differentiate into blood vessels or glands.

6. A method according to claim 5, wherein said scaffold comprises vessel endothelial cells or dermal microvascular endothelial cells (DMEC).

7. A method according to claim 6, wherein said vessel endothelial cells are derived from the umbilical cord.

8. A method according to claim 7, wherein said umbilical vessel endothelial cells are of human origin.

9. A method according to claim 1, wherein said first medium comprises a fibroblast growth medium together with fetal serum, such as fetal calf serum (FCS) or fetal bovine serum (FBS) in order to proliferate and differentiate said UCMC in fibroblasts.

10. A method according to claim 9, wherein said fibroblast growth medium is selected from the group consisting of KGM®

-Keratinocyte Medium (Cambrex), MEGM-Mammary Epithelial Cell Medium (Cambrex), EpiLife®

medium (Cascade Biologics), Green'"'"'s Medium, CMRL1066 (Mediatech, Inc.), M171 (Cascade Biologics), L-15 medium, Dulbecco'"'"'s Modified Eagle Medium (DMEM), DMEM-F12 and RPMI media.

11. A method according to claim 1, wherein said first medium is selected from a group consisting of a medium comprising about 90 to about 95% (v/v) fibroblast growth medium together with about 5 to about 10% fetal calf serum (FCS) or fetal bovine serum (FBS).

12. A method according to claim 11, wherein said first medium comprises about 90 to about 95% (v/v) CMRL1066 (Mediatech, Inc.) and about 5 to about 10% fetal calf serum (FCS).

13. A method according to claim 1, wherein said second medium comprises a medium adapted for the cultivation of keratinocyte when said scaffold comprises UCEC in order to proliferate and differentiate said UCEC in keratinocytes.

14. A method according to claim 13, wherein said second medium comprises a keratinocyte growth medium, a growth factor, insulin, transferrin and selenous acid.

15. A method according to claim 14, wherein said growth factor is selected from the group consisting of epidermal growth factor (EGF), insulin-like growth factor-1, platelet-derived growth factor-BB (PDGFb), transforming growth factor-13, keratinocyte growth factor (KGF), TGF-α

and amphiregulin.

16. A method according to claim 14, wherein said keratinocyte growth medium is selected from the group consisting of KGM®

-Keratinocyte Medium (Cambrex), MEGM-Mammary Epithelial Cell Medium (Cambrex), EpiLife®

medium (Cascade Biologics), Green'"'"'s Medium, CMRL1066 (Mediatech, Inc.), M171 (Cascade Biologics), L-15 medium, Dulbecco'"'"'s Modified Eagle Medium (DMEM), DMEM-F12 and RPMI media.

17. A method according to claim 13, wherein said second medium is selected from a group consisting of a medium comprising a kerationocyte growth medium, epidermal growth factor (EGF), insulin, transferrin and selenous acid;

a medium comprising EpiLife®

medium (Cascade Biologics), epidermal growth factor (EGF), insulin, transferrin and selenous acid; and

a medium comprising about 98.8 to about 99.4% (v/v) EpiLife®

medium (Cascade Biologics), about 0.2 to about 0.4% (v/v) insulin, about 0.2 to about 0.4% (v/v) transferrin, about 0.2 to about 0.4% (v/v) selenous acid and about 10 ng/ml epidermal growth factor (EGF).

18. A method according to claim 1, wherein the scaffold comprises a biodegradable material.

19. A method according to claim 1, wherein the scaffold comprises a material selected from the group consisting of agarose, polycaprolactone, niobium coated carbon, chitosan, collagen, hyaluronic acid, calcium phosphate, starch, hydroxyapatite, fibrin, alginate, poly-glycolic acid, carbon nano fibres, porous polycarbonate, polytetrafluoroethylene, polylactide and mixtures thereof.

20. A method according to claim 19, wherein the scaffold material is porous polycarbonate.

21. A method according to claim 2, wherein said extracellular matrix component is selected from the group consisting of collagen, elastin, intercellular adhesion molecules, laminin, heparin, fibronectin, proteoglycans, tenascin, fibrillin and mixtures thereof.

22. A method according to claim 21, wherein said extracellular matrix component is collagen type I.